SCHEMBL15835213

SCHEMBL15835213

CCn1c(CCC(=O)c2ccc(Cl)cc2)nnc1SCC(=O)Nc1ccc(Br)c(C)c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC27A1 Q6PCB7 2/20 0.48
▸ MAPT P10636 4/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ GAA P10253 2/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CDC25A P30304 1/20 0.45
▸ CDC25B P30305 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ PTGES O14684 1/20 0.45
▸ THRB P10828 1/20 0.44
▸ TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1898835 0.86 LMNA (0.59) GAAALDH1A1HPGDTSHRATM
SCHEMBL30774047 0.86 LMNA (0.59) GAAALDH1A1HPGDTSHRATM
SCHEMBL4208252 0.67 TSHR (0.70) MAPTGAAALDH1A1NPC1TSHR
SCHEMBL4200066 0.67 MEN1 (0.68) SLC27A1MAPTMAPK1GAAALDH1A1
SCHEMBL4213595 0.67 MAPK1 (0.62) MAPTMAPK1GAAALDH1A1TSHR
SCHEMBL4198177 0.67 TSHR (0.68) MAPTGAAALDH1A1NPC1TSHR
SCHEMBL15983682 0.66 ALDH1A1 (0.73) MAPTGAAALDH1A1HPGDRAB9A
SCHEMBL4210377 0.66 KMT2A (0.71) MAPK1GAAALDH1A1TSHRHTT
SCHEMBL4198392 0.65 LMNA (0.84) MAPTMAPK1GAAALDH1A1HPGD
SCHEMBL19520565 0.65 TSHR (0.69) MAPK1ALDH1A1HPGDTSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9504676-B2 Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-11-29 — — US disclosed
US-9504676-B2 Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-11-29 — — US disclosed
US-20140179679-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-06-26 — — US disclosed
US-20140179679-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179679-A1 MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES SYK, BTK, TYRO3 SLC27A1 1833/4885MAPT 4486/4885MAPK1 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback